{"id":990115,"date":"2026-08-05T07:56:23","date_gmt":"2026-08-05T11:56:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/"},"modified":"2026-08-05T07:56:23","modified_gmt":"2026-08-05T11:56:23","slug":"briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/","title":{"rendered":"BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1\/2a clinical study of Bria-PROS+ in prostate cancer<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Bria-PROS+ is BriaCell\u2019s next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components designed to enhance clinical efficacy <\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Bria-PROS+ program previously awarded $2 million grant from the US National Cancer Institute<\/em><br \/>\n          <\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, Aug.  05, 2026  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for Bria-PROS+ and issued a Study May Proceed letter, clearing the way for clinical evaluation of Bria-PROS+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for prostate cancer.<\/p>\n<p align=\"justify\">\u201cWe are pleased to announce FDA clearance of the IND for Bria-PROS+, our next-generation personalized immunotherapy for prostate cancer,\u201d stated Dr. William V. Williams, BriaCell\u2019s President &amp; CEO. \u201cBria-PROS+ is designed to activate multiple components of the immune system, which we believe has the potential to support meaningful therapeutic benefit with a favorable safety profile. We look forward to advancing Bria-PROS+ into the clinic as we work to develop new treatment options for patients with advanced prostate cancer.\u201d<\/p>\n<p align=\"justify\">In August 2025,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lh_E7JXq9F7gJ6aMJjhov4fmySqJC1uEUdnsjJQ1_eddtbc3SU8w6j66laKQBoT_-NliYhuEZoEvz76pvtaj3jUt3kMC7V9sH3ymaEGy8DbRh_BjYWaIY4kEo8HOFCzEoLw7ULlt8vEvzzeqfqwDcPEVDUDeQ0lN1EGRUNL9dT_6EWBNynLoiO9vw68hHN1DdXbcLo_Cp6uk_O-d5CH7DAwnqZLu7ei2z1_OcHeN9Bo=\" rel=\"nofollow\" target=\"_blank\">BriaCell was awarded a $2 million non-dilutive grant<\/a>\u00a0from the US National Cancer Institute to support the manufacturing and planned clinical evaluation of Bria-PROS+.<\/p>\n<p align=\"justify\">As <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6XnqAntL7vywxGwJw17DIbA7KYl9CMVo8DiP0unhSRQMNfDU4HaM-2gCBwK05n22w2g3-9XDqJHajK78DjTJSkMP7fQQIVuSQUN3w7FQcw5jB27F9nj5mYggaRl5HuXllg72d4IbGLoG-Aduj8o5yeaxmHTzONGuXV__Q6LBsBx8lVqqABjOOLPHubUGJqwY51afAgc_Oj4LKLuLiaTBFe42zVJN7IVI8DLsNVDIXc4=\" rel=\"nofollow\" target=\"_blank\">reported in BriaCell\u2019s preclinical poster presentation<\/a>, at the American Association of Cancer Research (AACR) Annual Meeting, Bria-PROS+ demonstrated activation of both adaptive and innate immune responses including activation of na\u00efve (resting) T-cells, dendritic cells and natural killer (NK) cells. BriaCell believes this multipronged immune activation may enhance clinical efficacy and help prevent immune escape in patients with prostate cancer.<\/p>\n<p align=\"justify\">BriaCell\u2019s Bria-PROS+ builds on the Company\u2019s oncology platform with its Bria-IMT\u2122 program, currently in its Phase 3 pivotal trial for metastatic breast cancer, its Bria-OTS\u2122 breast cancer clinical program, in which the first patient dosed experienced <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9iqUi97ZTNzmYgXGKzwM40io1dCnvy1AIoeAw6E7VgHD1Nk_A3p5j3NP_KYQTemCE5ajwNCv_SyJyd4IG5jSYFb4sTKvBAXQR6VEEeS3v9WqgxIAGpuAOA2nG8rwRG9A2XNWv_5fBYvxIUs9C_cJNcoFh0tbEn6MR-urd3OPmlSAGCjCMymT0_YjjkSqzEeDY9uH727vS6Ac6O0qpta8170UrM24UrptnrOVId8dKlc=\" rel=\"nofollow\" target=\"_blank\">sustained complete resolution of a lung metastasis<\/a>, and its Bria-BRES+\u2122 program, which recently received FDA clearance to initiate clinical evaluation of its enhanced, personalized, off-the-shelf cellular immunotherapy for breast cancer. Bria-PROS+, Bria-OTS and Bria-BRES+ programs are personalized immunotherapies, based on HLA matching between patients and the respective immunotherapy cell lines.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DV9g-N0NvOFWBxNxwLURqqqhawbuM8G3UbZa70QJFSz2EYO_XRfzWHKDUoVN0HiR7LnZjJb3BgK6N7BQvsH7yPPsruNXq5y9FlIeuLPkk4c=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the FDA clearance of the IND application and the planned initiation of a Phase 1\/2a clinical study of Bria\u2011PROS+, and expectations regarding the potential clinical benefits of the Bria\u2011OTS+ platform, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company\u2019s profiles on SEDAR+ at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T6ZstI22JDXkZaaRuXn0Je8O5OMS-dBOhIngXrLbL8gnlJQsbkF-fgR83bxZ0RBIM-6B4efDSCWTBAF-NC9LbNAfS0avwi_HCMcJZnD7m9Y=\" rel=\"nofollow\" target=\"_blank\"><strong>www.sedarplus.ca<\/strong><\/a> and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T6ZstI22JDXkZaaRuXn0JQ2xZQJMlWj0YXJwsAHB6HX3x8FY-uf5emftgu-J16fso01LpTVWj8bJ1GwZq3A8Dg==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jvnhV_8IEGdvjD943jKOil0kuFD-NaAnxY8xKcb0zUBS3xv1kX4JOmUmZQhgqAzycoU-18ysBMAKqTvExBOkaumkQGVXoCUcl7Ujjg5LWgw=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=96K5iA6wtphs-kMQ-En7_5Hk2O-0MeTbkD25D_41zgODYBEWtJegmkvYcrOKyB52q3aLw3XjJ120JMQBtCY9RM-NOw9FVgW6jUOf9YYn85c=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzkwMyM3NzU4ODA4IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/N2MxMmI5YWYtYWM2My00NDFmLWFhNzAtNjg2MmFhMTk2MDU2LTExMDIyMjktMjAyNi0wOC0wNS1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1\/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell\u2019s next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components designed to enhance clinical efficacy Bria-PROS+ program previously awarded $2 million grant from the US National Cancer Institute PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for Bria-PROS+ and issued a Study May Proceed letter, clearing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-990115","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1\/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell\u2019s next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components designed to enhance clinical efficacy Bria-PROS+ program previously awarded $2 million grant from the US National Cancer Institute PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for Bria-PROS+ and issued a Study May Proceed letter, clearing &hellip; Continue reading &quot;BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T11:56:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzkwMyM3NzU4ODA4IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer\",\"datePublished\":\"2026-08-05T11:56:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\\\/\"},\"wordCount\":765,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMzkwMyM3NzU4ODA4IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\\\/\",\"name\":\"BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMzkwMyM3NzU4ODA4IzIwOTA2NTg=\",\"datePublished\":\"2026-08-05T11:56:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMzkwMyM3NzU4ODA4IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMzkwMyM3NzU4ODA4IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer - Market Newsdesk","og_description":"FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1\/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell\u2019s next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components designed to enhance clinical efficacy Bria-PROS+ program previously awarded $2 million grant from the US National Cancer Institute PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for Bria-PROS+ and issued a Study May Proceed letter, clearing &hellip; Continue reading \"BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-05T11:56:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzkwMyM3NzU4ODA4IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer","datePublished":"2026-08-05T11:56:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/"},"wordCount":765,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzkwMyM3NzU4ODA4IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/","name":"BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzkwMyM3NzU4ODA4IzIwOTA2NTg=","datePublished":"2026-08-05T11:56:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzkwMyM3NzU4ODA4IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzkwMyM3NzU4ODA4IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-pros-clinical-study-in-prostate-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Receives FDA Clearance to Initiate Bria-PROS+\u2122 Clinical Study in Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/990115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=990115"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/990115\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=990115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=990115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=990115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}